Tetrabenazine in the treatment of hyperkinetic movement disorders

Expert Review of Neurotherapeutics

Volumn 6, Issue 1, 2006, Pages 7-17

  Kenney, Christopher ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chorea; Dopamine; Huntington's disease; Hyperkinetic movement disorders; Tardive dyskinesia; Tetrabenazine; Tics; Tourette's syndrome

Indexed keywords

ALPHA DIHYDROTETRABENAZINE; BETA DIHYDROTETRABENAZINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLONIDINE; DIHYDROTETRABENAZINE; DOPAMINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PIMOZIDE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; ANXIETY DISORDER; APATHY; ASPIRATION PNEUMONIA; ATAXIA; BALANCE DISORDER; BLURRED VISION; CLINICAL TRIAL; CONFUSION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; EPIGASTRIC PAIN; FALLING; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPERTHERMIA; HYPOTENSION; INSOMNIA; INVOLUNTARY MOVEMENT; LOW DRUG DOSE; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE SPASM; MYOCLONUS; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; PANIC; PARANOIA; PARESTHESIA; PARKINSONISM; PHARYNX DISEASE; PREVALENCE; PSYCHOSIS; PURPURA; QUALITY OF LIFE; REVIEW; SALIVATION DISORDER; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SUICIDE; TARDIVE DYSKINESIA; TIC; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEAKNESS;

ADRENERGIC UPTAKE INHIBITORS; CLINICAL TRIALS; DRUG TOLERANCE; EXPERT TESTIMONY; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MOVEMENT DISORDERS; TETRABENAZINE;

EID: 33645872123     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.1.7     Document Type: Review

References (90)

1. Ashcroft GW, Macdougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J. Ment. Sci. 107, 287-293 (1961).
2. Sattes H. The treatment of chorea minor with the monoamine liberator 'Nitoman'. Psychiatr. Neurol. (Basel). 140, 13-19 (1960).
3. Stumpf W. Untersuchungen uber 'Nitoman'. Psychiatr. Neurol. 140, 63-68 (1960).
4. Brandrup E. Reserpin og tetrabenacin ved chorea Huntington. Nord. Med. 4, 968-969 (1960).
5. Fog R, Pakkenberg H. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta. Neurol. Scand. 46, 249-251 (1970).
6. Toglia JU, McGlamery M, Sambandham RR. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. J. Clin. Psych. 39, 81-87 (1978).
7. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med. J. Aust. 1, 583-584 (1976).
8. Gilligan BS, Wodak J, Veale JL, Munro OR. Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med. J. Aust. 2, 1054-1056 (1972).
9. Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J. Neurol. Neurosurg. Psych. 35, 186-191 (1972).
10. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1, 104-107 (1974).
11. Kingston D. Tetrabenazine for involuntary movement disorders. Med. J. Aust. 1, 628-630 (1979).
12. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 31, 1051-1054 (1981).
13. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann. Neurol. 11, 41-47 (1982).
14. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv. Neurol. 37, 277-289 (1983).
15. Gimenez-Roldan S, Mateo D. Huntington's disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 4, 282-287 (1989).
16. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48, 358-362 (1997).
17. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin. Neuropharmacol. 25, 300-302 (2002).
18. Paleacu D, Paleacu D, Giladi N et al. Tetrabenazine treatment in movement disorders. Clin. Neuropharmacol. 27, 230-233 (2004).
19. Huntingtons Study Group. Tetrabenazine as anti-chorea therapy in Huntington's disease: a randomized controlled trial. Neurology (2005)(In press).
20. Frank S, Onodo W, Hunter C, et al. A randomized, double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington's disease treated with tetrabenazine. Ann. Neurol. (In Press) (2005).
21. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38, 391-394 (1988).
22. Vieregge P. Tetrabenazine in the treatment of senile vocal tics. J. Neurol. 235, 126-127 (1987).
23. Jimenez-Jimenez FJ, Garcia-Ruiz PJ. Pharmacological options for the treatment of Tourette's disorder. Drugs 61, 2207-2220 (2001).
24. Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 34, 688-692 (1984).
25. Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J. Neurol. Sci. 14, 541-546 (1987).
26. Tarsy D. Tardive Dyskinesia. Curr. Treat. Options Neurol. 2, 205-214 (2000).
27. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psych. 156, 1279-1281 (1999).
28. Fahn S. A therapeutic approach to tardive dyskinesia. J. Clin. Psych. 46, 19-24 (1985).
29. Scott BL. Evaluation and treatment of dystonia. South. Med. J. 93, 746-751 (2000).
30. Manji H, Howard RS, Miller DH. et al. Status dystonicus: the syndrome and its management. Brain 121(Pt 2), 243-252 (1998).
31. Hoehn MM, Cherington M. Spinal myoclonus. Neurology 27, 942-946 (1977).
32. Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch. Neurol. 43, 1025-1031 (1986).
33. Hunter C, Vuong K, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology 62(Suppl. 5), A506-A507 (2004).
34. Stacy M, Jankovic J. Tardive tremor. Mov. Disord. 1, 53-57 (1992).
35. Storey E, Lloyd J. Tardive tremor. Mov. Disord. 12, 808-810 (1997).
36. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol. 18, 197-214 (1995).
37. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J. Pharmacol. Exp. Ther. 127, 103-109 (1959).
38. Scherman D, Henry JP. Acido-basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie 64, 915-921 (1982).
39. Roberts MS, Watson HM, McLean S, Millingen KS. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J. Chromatogr. 226, 175-182 (1981).
40. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug. Metab. Dispos. 15, 250-255 (1987).
41. Roberts MS, McLean S, Millingen KS, Galloway HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur. J. Clin. Pharmacol. 29, 703-708 (1986).
42. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol. 102, 425-430 (1984).
43. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47, 331-339 (1986).
44. Pletscher A, Brossi A, Gey K. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol. 4, 275-306 (1962).
45. Lane JD, Smith JE, Shea PA, McBride WJ. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci. 19, 1663-1667 (1976).
46. Pearson SJ, Reynolds GP Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 27, 717-719 (1988).
47. Garcia Ruiz PJ, Mena MA, Sanchez Bernardos V. et al. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. Clin. Neuropharmacol. 18, 58-63 (1995).
48. Gonzalez AM, Walther D, Pazos A, Uhl, GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res. Mol. Brain Res. 22, 219-226 (1994).
49. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 93, 5166-5171 (1996).
50. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann. Neurol. 12, 257-262 (1982).
51. Reches A, Burke RE, Kuhn CM et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J. Pharmacol. Exp. Ther. 225, 515-521 (1983).
52. Burke R. E, Reches A, Traub MM. et al. Tetrabenazine induces acute dystonic reactions. Ann. Neurol. 17, 200-202 (1985).
53. Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br. J. Pharmacol. 61, 339-344 (1977).
54. Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J. Med. Genet. 32, 516-518 (1995).
55. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
56. McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. NZ Med. J. 83, 114-116 (1976).
57. Mikkelsen BO. Tolerance of tetrabenazine during long-term treatment. Acta. Neurol. Scand. 68, 57-60 (1983).
58. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am. J. Psych. 130, 479-483 (1973).
59. Jankovic J, Vuong K, Hunter C. Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov. Disord. 19, 1127 (2004).
60. Shannon J, Kaplan M, Pierce M. An interesting reaction to a tranquilizer: tonic seizures with perphenazine (Trilofon). Am. J. Psych. 114, 556 (1957).
61. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43, 937-941 (1993).
62. Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South. Med. J. 83, 525-532 (1990).
63. Pasricha P, Sugumar A, Jankovic, J. From disturbed motility to disordered movement: A review of the clinical and legal risks of metoclopramide. Nat. Gastr. (In Press) (2005).
64. Mejia N, Vuong K, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov. Disord. 20(Suppl. 10), S18 (2005).
65. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch. Gen. Psych. 27, 95-99 (1972).
66. Bartels M, Zeller E. Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video and EMG-controlled study. Eur. Arch. Psych. Neurosci. 234, 172-174 (1984).
67. Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can. J. Psychiatry 33, 11-13 (1988).
68. Jankovic J, Hunter C, Mejia N, Vuong K. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov. Disord. 19(Suppl. 9), S73 (2004).
69. Simpson G. M. The treatment of tardive dyskinesia and tardive dystonia. J. Clin. Psych. 61(Suppl. 4), 39-44 (2000).
70. Jankovic J. Tourette's syndrome. N. Engl. J. Med. 345, 1184-1192 (2001).
71. Kurlan R, Como PG, Miller P et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 59, 414-420 (2002).
72. Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv. Neurol. 58, 7-14 (1992).
73. Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov. Disord. 18, 1530-1533 (2003).
74. Sweet RD, Bruun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch. Gen. Psych. 31, 857-861 (1974).
75. Shapiro AK, Shapiro AS, Bruun R. Gilles de la Tourette Syndrome. Raven Press, NY, 212-214 (1978).
76. Hunter C, Vuong K, Mejia N, Jankovic J. Tetrabenazine, a monoamine depletor, effective in the treatment of Tourette's syndrome. Mov. Disord. 19(Suppl. 9), S437 (2004).
77. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov. Disord. 18, 703-706 (2003).
78. Vuong K, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov. Disord. 19(Suppl. 9), S422 (2004).
79. Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br. J. Clin. Pract. 26, 179-180 (1972).
80. Hunter C, Wang A, Vuong K, Jankovic J. Age-related tolerability of tetrabenazine. Mov. Disord. 17(Suppl. 5), S41 (2002).
81. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med. 24, 369-371 (1998).
82. Burke RE, Fahn S, Mayeux R et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Neurology 31, 1022-1025 (1981).
83. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin. Neuropharmacol. 15, 63-68 (1992).
84. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov. Disord. 11, 95 (1996).
85. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov. Disord. 12, 246-248 (1997).
86. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott. Med. J. 17, 367-370 (1972).
87. Shoulson I, Goldblatt D. Huntington's disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features. Neurology 31, 79 (1981).
88. Jahan MS, Farooque AI, Wahid Z. Neuroleptic malignant syndrome. J. Natl. Med. Assoc. 84, 966-970 (1992).
89. Snaith RP, Warren HD. Letter: Treatment of Huntington's chorea with tetrabenazine. Lancet 1, 413-414 (1974).
90. Thiriot DS, Ruoho AE. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J. Biol. Chem. 276, 27304-27315 (2001).